Developed a rash all over her body; Achy; Feverish; Nausea; Vomiting; Spontaneous report received on 05FEB2020. Additional information received on 07FEB2020.  A nurse reported that a 30-year-old young and healthy female consumer had nausea (PT: Nausea), vomiting (PT: Vomiting) and was feverish (PT: Pyrexia) while being on Vivotif (Typhoid vaccine live oral Ty21A) capsule and MMR (measles, mumps and rubella vaccine) for immunisation. On29JAN2020, she received MMR vaccine. She took first and second dose of Vivotif on 01FEB2020 at 10:00 am and 03FEB2020 at 10:00 am, respectively. On 04FEB2020, she felt sick and had nausea, fever and threw up in night. She could not remember the date when she took third dose of Vivotif, whether she took it around 10:00 am on 04 FEB2020 or 10:00 am on 05FEB2020. She had not taken the last dose yet. She had not received any treatment for nausea, vomiting and fever although she stayed hydrated and slept. Action taken with Vivotif with respect to the reported events was unknown, and action taken with MMR with respect to the reported events was not applicable. All the symptoms were resolved on 06FEB2020.  Company Comment: A consumer had nausea, vomiting and pyrexia after taking Vivotif doses. The consumer also took MMR vaccine a few days before she took Vivotif dose. The events resolved within two days without any treatment. The consumer has not taken the last dose of Vivotif yet. Considering the case information, and the potential of Vivotif to cause nausea, vomiting and pyrexia, the causality of all events is assessed as possible with Vivotif (confounded by MMR vaccine).  Follow up information received on 22MAY2020 in VAERS report.  The follow up information received included updated events, action taken, and lot number of Vivotif.  The lot number (3003302) and route of administration (oral) of Vivotif was updated. It was updated that on 04FEB2020, the consumer also felt "achy" (PT: Pain).   It was reported that the consumer felt much better and was having no fever and was keeping food down. So, she took the fourth dose of Vivotif on 07FEB2020.  On 10FEB2020, she reported that she "developed a rash all over her body" (PT: Rash).  Action taken with Vivotif with respect to the events nausea, vomiting, and feverish was updated to dose not changed.  Action taken with Vivotif with respect to the updated events "developed a rash all over her body" was not applicable and with the updated event "achy" was dose not changed.  The consumer had recovered from reported events "developed a rash all over her body" and "achy".  Company Comment: A consumer was achy (pain), and had nausea, vomiting and pyrexia after taking second dose of vivotif, The consumer also developed rash all over her body (rash) after two days of taking the last dose of vivotif. The consumer also took MMR vaccine a few days before she took Vivotif dose. The events (nausea, vomiting, pain and pyrexia) resolved within two days without any treatment. The consumer did not interrupt taking vivotif dose and took last dose of Vivotif as per the schedule. Considering the case information, and the potential of Vivotif to cause nausea, vomiting, rash, pyrexia, and also myalgia, the causality of all the reported events is assessed as possible with Vivotif (confounded by MMR vaccine).; Sender's Comments: A consumer was achy (pain), and had nausea, vomiting and pyrexia after taking second dose of vivotif, The consumer also developed rash all over her body (rash) after two days of taking the last dose of vivotif. The consumer also took MMR vaccine a few days before she took vivotif dose. The events (nausea, vomiting, pain and pyrexia) resolved within two days without any treatment. The consumer did not interrupt taking vivotif dose and took last dose of Vivotif as per the schedule. Considering the case information, and the potential of Vivotif to cause nausea, vomiting, rash, pyrexia, and also myalgia, the causality of all the reported events is assessed as possible with Vivotif (confounded by MMR vaccine).